<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

3D Ex Vivo Patient Tissue Platform: Answers to Your Top 10 Questions

Patient-derived 3D ex vivo platforms are playing an increasingly important role in drug discovery. These translational platforms are high-throughput and highly clinically relevant because they accurately recapitulate the heterogeneity and molecular/genetic complexity observed in human tumors, including intact endogenous immune cell populations, fibroblasts, and other stromal components.

Crown Bioscience’s webinar, “Elevate Your Insights into the Tumor Microenvironment: 3D Ex Vivo Patient Tissue Platform”, discussed many important topics, including how this platform can be leveraged to evaluate monotherapy and combination drug responses in patient tumor samples with endogenous tumor microenvironment (TME) cell populations intact.

This blog post explores the value of 3D ex vivo patient tissue platforms in drug discovery and addresses key questions that arose from the webinar.

The Value of 3D Ex Vivo Platforms in Drug Discovery

The 3D ex vivo patient tissue platform can improve clinical success rates because it relies on patient-derived tumor samples—isolated from biopsies, surgical resections, ascites, and pleural effusions—that are highly predictive of tumor response to drug candidates. Its possible applications are wide ranging, but many researchers are using it to measure oncology and immuno-oncology drug-induced tumor killing and endogenous immune cell proliferation. 

Furthermore, pairing the 3D ex vivo patient tissue platform with automated high content imaging and image analysis allows for measuring more than 500 phenotypic changes to provide a highly comprehensive evaluation of response to treatment at different doses, combinations, and timepoints simultaneously. Overall, this translational system provides reliable, reproducible data that is clinically relevant and can support important decisions throughout your drug discovery and development workflow. 
  3d-ex-vivo-patient-tissue-platform-transformed (2)
Figure 1: 3D Ex Vivo Patient Tissue Assay Principle.

Webinar Recap: Key Questions and Answers

Are all patient samples at the same cancer stage?

No. We receive samples from all different stages. For optimal tumor viability, the samples are from patients who are treatment naive or have not received treatment over the past 6 months.

Is the same matrix used for all samples?

Our proprietary platform uses an optimized matrix composition that is applicable for almost all tumor types tested to date. However, the specific media composition tends to vary by indication.

How often are new samples received?

This largely depends on the indication. For instance, our trusted and accredited tissue providers are able to provide 2–3 NSCLC samples per week. For rarer indications, such as melanoma and glioblastoma, we typically receive 1–3 samples per month.

Have approved immuno-oncology drugs been tested using the 3D ex vivo patient tissue model?

Absolutely. The majority of clinically approved checkpoint inhibitors have been tested, including pembrolizumab, ipilimumab, nivolumab, durvalumab, atezolizumab, and ADU-S100.

Regarding preselection markers—if a selection marker is not available in the clinic, can this be evaluated later during the culture process in order to assess it?

Yes. A piece of the original tumor sample can be used for additional characterization, such as IHC, FACS, or sequencing. 

What turnaround time can I expect for a typical drug testing assay?

On average, it takes 8–10 weeks from the time of first drug exposure to final reporting. The actual assay time is relatively short. However, a significant amount of time is required for other steps, such as fixation and staining, imaging, image analysis, data analysis, and development of the final report. Quality control is also evaluated at every step. 

Can co-cultures of matching organoids and TILs be generated from the same tumor Sample?

Our ex vivo patient tissue platform uses only fresh patient material that contains all the endogenous components of the tumor microenvironment. Crown Bioscience’s IO team is working to develop matching organoid-TIL co-cultures.

Can patients be preselected based on specific selection criteria, such as EGFR expression?

This is only possible if the biomarker is routinely evaluated in the clinic, such as ER, PR, and HER2 in breast cancer. While it is less common, EGFR expression is possible because it is used for some cancer types.

How are patient samples transported to ensure sample integrity is maintained?

Samples are cold shipped in a medium that preserves cell viability, such as Aqix or HypoThermosol. 

Can we run a repeated assay on cryopreserved material?

This is theoretically possible, but the nature of the compounds must be considered. For instance, testing IO compounds on cryopreserved material is not recommended because the integrity of immune cell subsets, such as macrophages, is known to be lost/depleted with freezing/thawing. 

Learn more about the expanding indications of our 3D Ex Vivo Patient Tissue Platform.

Download The Poster Now

Related Posts